LGF
ABMD

LGT Group Foundation’s Abiomed Inc ABMD Stock Holding History

LGT Group Foundation’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,979
Closed -$12M – 277
2022
Q3 		$12M Buy
48,979
+2,979
+6% +$804K 0.47% 53
2022
Q2 		$11.4M Sell
46,000
-9,670
-17% -$2.61M 0.35% 67
2022
Q1 		$18.9M Buy
55,670
+19,168
+53% +$5.9M 0.44% 53
2021
Q4 		$13.1M Buy
+36,502
New +$12.3M 0.34% 75

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

LGT Group Foundation's ABMD Position: Q4 2022 in Review

LGT Group Foundation sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 48,979 shares — an estimated $12M sold.

LGT Group Foundation first reported a position in ABMD in Q4 2021 and held it in 4 quarters. The position peaked at $18.9M in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • LGT Group Foundation reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • LGT Group Foundation sold 48,979 Abiomed Inc shares in Q4 2022, an estimated $12M.
  • LGT Group Foundation first reported a position in Abiomed Inc in Q4 2021 and held it in 4 quarters.
  • LGT Group Foundation's Abiomed Inc position peaked at $18.9M in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on LGT Group Foundation's 13F filing for Q4 2022, filed 9 Feb 2023.